Pioneer in living medicines
- Deals closed with pharma companies in U.S., Asia and Europe
- Trade sale of spin-off Redvax to Pfizer (press release) for its CMV vaccine program and a further undiclosed program.
- Internationally recognized scientists as scientific advisors
- Engineering and production of >100 novel proteins and protein complexes
- First company having successfully developed stable CMV pentamer at >95% purity
Redbiotec expands its expertise – two new appointments
Redbiotec welcomes two new senior people. Dr. Jin Huh, synthetic biology expert and scientific advisor to Redbiotec, postdoctoral associate of [...]
Collaboration with LOVIT/ Dr. Antonio Marchini
Redbiotec is pleased to announce the appointment of Dr. Antonio Marchini, head of Laboratory of Oncolytic-Virus-Immuno-Therapeutics (LOVIT) at the Luxembourg Institute [...]
Tumor immunology expert joining Redbiotec’s SAB
Redbiotec is pleased to welcome Prof. Maries van den Broek, PhD, Professor at the University of Zurich, Institute of Experimental Immunology, [...]
Growing traction and growing team for Redbiotec’s oncology program
Big and growing interest in Redbiotec's COMOS and in Redbiotec's engineered bacteria carrying CRISPR. Redbiotec therefore further invests in its promising IO platforms.